Jan Nilsson has been appointed chief operating officer at NeuroVive Pharmaceutical AB in Sweden which is developing products for acute cardiovascular and neurological conditions. Mr Nilsson has more than 30 years of experience in commercial and sales roles in the biopharma industry, mostly recently as managing director of Lipopeptide AB and as chief commercial officer at Pergamum AB, two clinical-stage Swedish biotech companies. He also served as managing director of Tripep AB, a Swedish biotech company developing therapeutic DNA vaccines against hepatitis B and C. Mr Nilsson has been a member of the NeuroVive board since 2011, but will not be standing for re-election owing to his new role with the company.
NeuroVive announced the appointment on 1 February 2013.
Copyright 2013 Evernow Publishing Ltd.